Anti-Cancer Drug Design

Structural and functional analysis of the control region of the human DNA topoisomerase II gene in drug-resistant cells
pp. 87-92(6)
Authors: Takano H.; Ise T.; Nomoto M.; Kato K.; Murakami T.; Ohmori H.; Imamura T.; Nagatani G.; Okamoto T.; Ohta R.; Furukawa M.; Shibao K.; Izumi H.; Kuwano M.; Kohno K.

Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy
pp. 93-106(14)
Authors: Desbene S.; Van H-T.; Michel S.; Tillequin F.; Koch M.; Schmidt F.; Florent J-C.; Monneret C.; Straub R.; Czech J.; Gerken M.; Bossiet K.

Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma
pp. 107-114(8)
Authors: Osada M.; Ishioka C.; Ichinohasama R.; Kadowaki I.; Murakawa Y.; Watanabe M.; Kanamaru R.; Ikawa S.

Recent progress in P-glycoprotein research
pp. 115-121(7)
Authors: Ueda K.; Yoshida A.; Amachi T.

Multidrug resistance-associated protein subfamily transporters and drug resistance
pp. 123-131(9)
Authors: Kuwano M.; Toh S.; Uchiumi T.; Takano H.; Kohno K.; Wada M.

Cytoskeletons and antimitotic agents developed in Japan
pp. 133-141(9)
Authors: Nishio K.; Saijo N.

Resistance to cisplatin
pp. 143-151(9)
Authors: Akiyama S-i.; Chen Z-S.; Sumizawa T.; Furukawa T.

Adhesion-dependent multicellular drug resistance
pp. 153-168(16)
Authors: Green S.; Frankel A.; Kerbel R.

Drug resistance mediated by cellular stress response to the microenvironment of solid tumors
pp. 169-177(9)
Authors: Tomida A.; Tsuruo T.